Janus Kinase Inhibitors And The Risk Of Major Adverse Cardiovascular Events, Thrombosis (including Fatal Events) And Malignancy
Recall Summary The FDA is warning about six Janus Kinase Inhibitor medications (CIBINQO, INREBIC, JAKAVI, OLUMIANT, RINVOQ, and XELJANZ/XELJANZ XR) due to new safety data showing increased risks of serious heart problems, blood clots, and cancer. These drugs are used to treat conditions like rheumatoid arthritis and other inflammatory diseases. The warning affects all Canadian patients currently using or prescribed these medications.
- Product
- CIBINQO (abrocitinib), INREBIC (fedratinib), JAKAVI (ruxolitinib), OLUMIANT (baricitinib), RINVOQ (upadacitinib), XELJANZ/XELJANZ XR (tofacitinib)
- Reason
- New safety information - Product safety
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2022-10-31
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/517d888f-fb41-4f6a-928b-87e4b4c4520b